Farrow Financial, Inc.
Position in LCTX — Lineage Cell Therapeutics, Inc.
CIK 2010644
SOUTH BURLINGTON, VT
Position in LCTX
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$13,946
-$4,224 QoQ
Shares Held
10,646
-7.4% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#91
of 130 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LCTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Farrow Financial, Inc. holds $1,085,275 across 2 Biotechnology names. LCTX ranks #2 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CRSP |
CRISPR Therapeutics AG
|
19,643 | $1,071,329 | |
| 2 | LCTX |
Lineage Cell Therapeutics, Inc.
This page
|
10,646 | $13,946 |
All Filings in LCTX
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13,946 | 10,646 | Shares | Sole | 2026-08-04 | |
| 2026-03-31 | $18,170 | 11,500 | Shares | Sole | 2026-05-01 | |
| 2025-12-31 | $19,205 | 11,500 | Shares | Sole | 2026-01-27 | |
| 2025-09-30 | $19,435 | 11,500 | Shares | Sole | 2025-11-03 | |
| 2025-06-30 | $10,465 | 11,500 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $5,175 | 11,500 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $5,750 | 11,500 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $10,465 | 11,500 | Shares | Sole | 2024-10-24 | |
| 2024-06-30 | $11,500 | 11,500 | Shares | Sole | 2024-07-15 | |
| 2024-03-31 | $17,020 | 11,500 | Shares | Sole | 2024-05-02 | |
| 2023-12-31 | $18,530 | 17,000 | Shares | Sole | 2024-02-08 | |
| No filing history on record for this holder in this stock. | ||||||